Tag: oncolytic
TRANSGENE: The positive data generated in 2022 with the main clinical candidates confirms Transgene’s outlook for 2023, in a buoyant context for therapeutic vaccines against cancer and oncolytic viruses – 03/16/2023 at 17:45
2022 annual results and activity update – TG4050: New Phase I data confirms the clinical and commercial potential of this innovative personalized immunotherapy. Preparation of a Phase II trial in…
Transgene: Positive data on key clinical candidates delivered in 2022 – Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum – 03/16/2023 at 17:45
2022 Full-year results and business update – TG4050: New Phase I data confirms the strong clinical and commercial potential of this highly innovative personalized immunotherapy. Preparing for a Phase II…
Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022 – 11/14/2022 at 08:00
Winning paper demonstrates potential of vectorized novel CTLA-4 targeting antibodies and was highlighted at SITC 2022 Reaffirms potential of BT-001, an oncolytic virus co-developed by Transgene and BioInvent currently in…
Transgene and BioInvent win the Best Article award in the Oncolytic and Local Immunotherapy category awarded by the JITC, for their work on BT-001 – 2022-11-14 at 08:00
Article, Featured at SITC 2022, Demonstrates the Potential of Innovative Anti-CTLA-4 Antibody Delivery This award further highlights the potential of BT-001, an oncolytic virus co-developed by Transgene and BioInvent, currently…
Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022 – 09/12/2022 at 08:00
Additional positive TG6002 Phase I data show that the oncolytic virus is able to reach the tumor, replicate and express its payload in all patients when administered intravenously Strasbourg, France,…
Phase I data of TG6002 presented at ESMO 2022 confirms the potential of Transgene’s Invir.IO™ oncolytic viruses administered intravenously to treat solid tumors – 09/12/2022 at 08:00
The new positive data from the Phase I trial of TG6002 show in all patients that this oncolytic virus, administered intravenously, is capable of reaching the tumor, multiplying there and…
Transgene: new positive data for its oncolytic virus TG6002 – 09/12/2022 at 08:52
(AOF) – Transgene has announced new positive data from the Phase I trial combining intravenous (IV) administration of the oncolytic virus TG6002 and oral intake of 5-FC in patients with…